Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Food safety diagnostics might feel far from Wall Street, yet Neogen’s supply-chain complexity shows up in hundreds of pages of disclosures. Tracking which genomic test kit drives revenue, or when management sells shares, is difficult. That’s why investors hunting for “Neogen insider trading Form 4 transactions” or the latest “Neogen quarterly earnings report 10-Q filing” often lose hours scrolling through EDGAR.
Stock Titan fixes this. Our AI reads every 10-K, 10-Q, 8-K and proxy the moment it is released, pushes “Neogen Form 4 insider transactions real-time” to your dashboard, and offers “Neogen SEC filings explained simply” with crisp language and data visualizations. Within seconds you’ll see a “Neogen earnings report filing analysis,” flagging segment sales for food safety, animal safety and genomics, plus cash flow shifts tied to acquisitions. Interactive links jump you straight to risk factors, while sidebars answer “understanding Neogen SEC documents with AI” without legalese.
Want specifics? The “Neogen annual report 10-K simplified” highlights R&D spend on LAMP molecular assays and global compliance costs. The “Neogen proxy statement executive compensation” module benchmarks pay packages against peer diagnostics firms. Alerts on “Neogen executive stock transactions Form 4” reveal buying patterns before material announcements, and our dashboard keeps the “Neogen 8-K material events explained” in plain sight when recalls or mergers hit. Whether you compare quarter-over-quarter allergen test kit sales, monitor insider sentiment, or review governance votes, Stock Titan delivers the intelligence you need, updated in real time and ready for decision making.
Neogen Corporation filed an 8-K/A to correct its Annual Meeting results, confirming that Proposal 2 (say‑on‑pay) was approved on October 23, 2025. Shareholder participation was strong, with 195,086,461 of 217,298,626 shares outstanding and entitled to vote present and voted.
Proposal 2 received 167,126,873 For, 17,679,601 Against, 412,667 Abstain, and 9,805,786 broker non‑votes. Shareholders also ratified the appointment of BDO USA, P.C. as auditor with 181,630,320 For, 13,148,285 Against, and 307,856 Abstain. Director nominees Thierry L. Bernard, Mikhael Nassif, Avi Pelossof, and Andrea F. Wainer each received a majority of votes For.
Neogen Corporation reported results from its 2025 Annual Meeting held on October 23, 2025. A total of 195,086,461 of 217,298,626 shares outstanding and entitled to vote were represented.
Shareholders elected four directors: Thierry L. Bernard (For 168,950,135; Withheld 16,330,540), Mikhael Nassif (For 171,847,536; Withheld 13,433,139), Avi Pelossof (For 171,839,634; Withheld 13,441,041), and Andrea F. Wainer (For 169,573,203; Withheld 15,707,472).
The non-binding advisory vote on executive compensation did not pass (For 167,126,873; Against 17,679,601; Abstain 412,667; Broker Non-Vote 9,805,786). Shareholders ratified BDO USA, P.C. as independent auditor for the fiscal year ending May 31, 2026 (For 181,630,320; Against 13,148,285; Abstain 307,856).
Neogen Corp (NEOG) reported an insider equity event. On 10/13/2025, the Chief Legal Officer had 294 RSUs vest and settle into an equal number of common shares (Code M) at a stated price of $6.04 per share. To satisfy tax obligations, 115 shares were withheld/disposed (Code F) at $6.04. Following these transactions, the officer directly owns 49,851 shares.
Neogen Corp (NEOG) reported an insider equity event by a company officer (Former COO). On 10/13/2025, 783 restricted stock units vested and were settled for an equal number of common shares (transaction code M). To satisfy tax withholding, 383 shares were withheld/disposed (code F) at a price listed as $6.04 per share. Following these transactions, the reporting person directly owned 88,858 common shares.
Neogen Corp (NEOG) insider filing reports routine equity compensation activity. An officer (Former CEO) converted 3,063 restricted stock units into common stock on 10/13/2025 (Code M) at $6.04 per share, and recorded a disposition of 865 shares (Code F) at $6.04 per share the same day. After these transactions, the reporting person beneficially owned 332,849 shares, held directly.
The remarks state each RSU is the economic equivalent of one share, and these RSUs vested and were settled for an equal number of common shares on October 13, 2025.
NEOGEN CORP (NEOG) reporting person Amy M. Rocklin had 9,036 restricted stock units vest on
Insider stock vesting and sale by former COO
On
The filing states each RSU equals one share and that vesting and settlement occurred on
Insider stock activity at NEOGEN (NEOG): Former CEO and officer John Edward Adent had 32,936 restricted stock units vest on
Catherine E. Woteki, a director of NEOGEN CORP (NEOG), had
The filing is a routine Section 16 Form 4 reporting the vesting and settlement of equity compensation; it shows an increase in the director’s direct holdings but does not disclose any cash sale or purchase beyond the RSU settlement.
Tobin James P, a director of Neogen Corp (NEOG), had 2,071 restricted stock units vest on
FAQ
What is the current stock price of Neogen (NEOG)?
What is the market cap of Neogen (NEOG)?
